Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19364654 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | October 2025 | February 2026 | Allow | 4 | 1 | 0 | No | No |
| 19274280 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19264673 | TREATMENT OF PROSTATE CANCER | July 2025 | September 2025 | Allow | 2 | 0 | 0 | No | No |
| 19231124 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | September 2025 | Allow | 4 | 0 | 0 | No | No |
| 19229702 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19228293 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228565 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19228179 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19206788 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | May 2025 | July 2025 | Allow | 2 | 1 | 0 | No | No |
| 19187858 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | April 2025 | May 2025 | Allow | 1 | 0 | 0 | No | No |
| 19182463 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19171162 | METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS | April 2025 | July 2025 | Allow | 3 | 0 | 0 | No | No |
| 19094703 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | March 2025 | June 2025 | Allow | 3 | 2 | 0 | No | No |
| 19094716 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19094756 | METHODS FOR MAKING AND USING ENDOXIFEN | March 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19087148 | METHODS OF TREATMENT | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19079727 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19076811 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | March 2025 | July 2025 | Allow | 4 | 0 | 0 | No | No |
| 19050547 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19039220 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | January 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 18990351 | METHODS OF IMPROVING RENAL FUNCTION | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18949037 | Methods for Providing Rapid Relief of Motor Fluctuations in a Parkinson's Disease Patient | November 2024 | July 2025 | Allow | 8 | 1 | 0 | No | No |
| 18943210 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18938942 | Oral Testosterone Therapy | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18937891 | TREATMENT OF PROSTATE CANCER | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18899500 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18818317 | STABLE PSILOCIN SALTS, ESTERS AND CONJUGATES AND USES THEREOF | August 2024 | November 2024 | Allow | 2 | 1 | 0 | No | No |
| 18838986 | MORPHOLINE-LIKE MONOAMINE RELEASERS | August 2024 | May 2025 | Allow | 9 | 1 | 0 | No | No |
| 18765632 | DOSAGE FORMS OF MIRDAMETINIB | July 2024 | July 2025 | Allow | 12 | 1 | 0 | No | No |
| 18763671 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF A CANCER | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18758242 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18758904 | TREATMENT OF PROSTATE CANCER | June 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18734541 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18708597 | MONTELUKAST BERBERINE QUATERNARY AMMONIUM SALT COMPOUND AND DOUBLE SALT COMPOSITION, AND SYNTHESIS METHOD THEREFOR AND USE THEREOF | May 2024 | September 2024 | Allow | 4 | 0 | 0 | No | No |
| 18657665 | METHODS FOR MAKING AND USING ENDOXIFEN | May 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
| 18641597 | Oral Testosterone Therapy | April 2024 | July 2024 | Allow | 3 | 1 | 0 | No | No |
| 18637711 | METHODS FOR TREATING HETEROTOPIC OSSIFICATION | April 2024 | June 2024 | Allow | 2 | 0 | 0 | No | No |
| 18608735 | DOSAGE FORMS OF MIRDAMETINIB | March 2024 | May 2024 | Allow | 2 | 0 | 0 | No | No |
| 18604836 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | March 2024 | May 2024 | Allow | 2 | 0 | 0 | No | No |
| 18582561 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | February 2024 | July 2025 | Allow | 17 | 2 | 0 | No | No |
| 18437724 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | February 2024 | November 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18437920 | NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIES | February 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18428522 | FORMULATIONS OF AN AXL/MER INHIBITOR | January 2024 | February 2025 | Allow | 12 | 0 | 0 | No | No |
| 18419852 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | January 2024 | March 2024 | Allow | 2 | 1 | 0 | No | No |
| 18413575 | CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF | January 2024 | January 2025 | Allow | 12 | 0 | 0 | No | No |
| 18393798 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | December 2023 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18544561 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18540835 | 1-HEXYL-5-(4-METHOXYPHENYL)-2,4-DIPHENYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18534509 | Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same | December 2023 | April 2025 | Allow | 16 | 0 | 0 | No | No |
| 18523609 | METHODS OF IMPROVING RENAL FUNCTION | November 2023 | July 2025 | Allow | 19 | 0 | 0 | No | No |
| 18565161 | THERAPEUTIC METHOD FOR CAT WITH CHRONIC KIDNEY DISEASE | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18521801 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | November 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18517156 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | November 2023 | November 2024 | Allow | 12 | 0 | 0 | No | No |
| 18499120 | METHODS FOR MAKING AND USING ENDOXIFEN | October 2023 | December 2024 | Allow | 13 | 0 | 0 | No | No |
| 18496074 | EZH2 INHIBITORS FOR TREATING CANCER | October 2023 | May 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18492833 | TRANSDERMAL DELIVERY FORMULATIONS | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18382939 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18488324 | ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE | October 2023 | May 2025 | Allow | 19 | 1 | 0 | No | No |
| 18487668 | TRANSDERMAL DELIVERY FORMULATIONS | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18483615 | Methods of Treating Pruritus | October 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18378019 | SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF | October 2023 | April 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18475841 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | September 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18476138 | TRANSMUCOSAL METHODS FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | September 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18472037 | AGENT FOR ELIMINATING SENESCENT CELLS | September 2023 | October 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18370926 | TREATING IRON DEFICIENCY WITH FERRIC CARBOXYMALTOSE | September 2023 | September 2024 | Allow | 12 | 0 | 0 | No | No |
| 18369913 | Prevention and Treatment of Viral Infections | September 2023 | April 2024 | Allow | 7 | 1 | 0 | No | No |
| 18368709 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18461724 | GLUTAMINASE INHIBITOR THERAPY | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18242317 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18235474 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING LOSS AND/OR DISTORTION OF TASTE OR SMELL | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18451452 | COMBINATION THERAPIES | August 2023 | March 2025 | Allow | 19 | 2 | 0 | No | No |
| 18366060 | METHODS OF TREATMENT | August 2023 | December 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18230099 | APILIMOD COMPOSITIONS AND METHODS OF USE | August 2023 | November 2025 | Allow | 28 | 0 | 0 | No | No |
| 18363779 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | August 2023 | November 2025 | Allow | 27 | 0 | 0 | No | No |
| 18358937 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | March 2024 | Allow | 8 | 1 | 0 | No | No |
| 18358936 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | October 2023 | Allow | 3 | 1 | 0 | No | No |
| 18358931 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | September 2023 | Allow | 2 | 0 | 0 | No | No |
| 18358934 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | September 2023 | Allow | 2 | 0 | 0 | No | No |
| 18358929 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | October 2023 | Allow | 3 | 0 | 0 | No | No |
| 18358926 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | July 2023 | October 2023 | Allow | 3 | 0 | 0 | No | No |
| 18273397 | METHODS AND COMPOSITIONS FOR TREATING 4- HYDROXYPHENYLPYRUVATE DIOXYGENASE-LIKE (HPDL)-RELATED DISEASES OR DISORDERS | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18223581 | NEFOPAM DOSAGE FORMS AND METHODS OF TREATMENT | July 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18223355 | METHODS OF IMPROVING RENAL FUNCTION | July 2023 | June 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18223340 | METHODS OF IMPROVING RENAL FUNCTION | July 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18352999 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | July 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18350103 | CRYSTALLINE 5-METHOXY-N,N-DIALLYLTRYPTAMINE COMPOUNDS | July 2023 | May 2025 | Allow | 22 | 1 | 0 | No | No |
| 18349220 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | July 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18346029 | METHODS OF TREATING CHOLANGIOCARCINOMA | June 2023 | September 2024 | Allow | 14 | 0 | 0 | No | No |
| 18211792 | METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION | June 2023 | March 2025 | Allow | 21 | 1 | 0 | No | No |
| 18268603 | Exo VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection | June 2023 | March 2026 | Allow | 33 | 0 | 0 | No | No |
| 18257660 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18334596 | METHODS FOR IMPROVING VISION | June 2023 | September 2024 | Allow | 15 | 1 | 0 | No | No |
| 18267432 | ERAP INHIBITORS | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18266345 | APPLICATION OF JAK INHIBITOR IN KIDNEY DISEASE | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18326279 | Methods Of Treating Fabry Patients Having Renal Impairment | May 2023 | April 2024 | Allow | 11 | 1 | 0 | No | No |
| 18326281 | Methods Of Treating Fabry Patients Having Renal Impairment | May 2023 | May 2024 | Allow | 11 | 2 | 0 | No | No |
| 18326274 | Methods Of Treating Fabry Patients Having Renal Impairment | May 2023 | April 2024 | Allow | 11 | 2 | 0 | No | No |
| 18319425 | TRANSMUCOSAL METHODS FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS | May 2023 | November 2024 | Allow | 18 | 1 | 0 | No | No |
| 18197380 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | May 2023 | December 2024 | Allow | 19 | 1 | 0 | No | No |
| 18316318 | CHARACTERIZATION OF THE ORAL MICROBIOME FOR THE NON-INVASIVE DIAGNOSIS OF BARRETT'S ESOPHAGUS | May 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HENLEY III, RAYMOND J.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HENLEY III, RAYMOND J works in Art Unit 1629 and has examined 1,194 patent applications in our dataset. With an allowance rate of 88.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 17 months.
Examiner HENLEY III, RAYMOND J's allowance rate of 88.4% places them in the 69% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HENLEY III, RAYMOND J receive 0.97 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HENLEY III, RAYMOND J is 17 months. This places the examiner in the 97% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -0.5% benefit to allowance rate for applications examined by HENLEY III, RAYMOND J. This interview benefit is in the 11% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 41.3% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 69.8% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 84.2% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 81.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.5% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.9% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.